Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

Background: Berotralstat is a once-daily oral inhibitor of plasma kallikrein for the prophylaxis of hereditary angioedema (HAE) in patients ≥12 years. APeX-J aimed to evaluate the efficacy and safety of berotralstat in Japan. Methods: APeX-J was a Phase III trial comprising 3 parts (NCT03873116). Pa...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Daisuke Honda, MD, PhD, Michihiro Hide, MD, PhD, Tomoo Fukuda, MD, PhD, Keisuke Koga, MD, PhD, Eishin Morita, MD, PhD, Shinichi Moriwaki, MD, Yoshihiro Sasaki, MD, PhD, Yusuke Suzuki, MD, PhD, Phil Collis, PhD, Douglas T. Johnston, DO, Dianne Tomita, MPH, Bhavisha Desai, PharmD, Isao Ohsawa, MD, PhD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-03-01
coleção:	World Allergy Organization Journal
Assuntos:	Angioedemas Hereditary Berotralstat Japan Plasma kallikrein Quality of life
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1939455124000139
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!